06 Март, 2003
Гениальность и помешательство - Чезаре Ломброзо
06 Март, 2003
Mania indication sought for Seroquel in Europe - Bipolar Disorder
AstraZeneca has submitted an application to the 14 European Member States involved in the Mutual Recognition Procedure for Seroquel to be granted a license for the treatment of manic episodes associated with bipolar disorder . Medical Letter on the CDC & FDA via NewsEdge Corporation : AstraZeneca has submitted an application to the 14 European Member States involved in the Mutual Recognition Procedure for Seroquel (quetiapine) to be granted a license for the treatment of manic episodes associated with bipolar disorder (manic-depressive illness). The Type II license variation application to Seroquel's existing schizophrenia marketing authorization means that the drug is now currently under regulatory review for bipolar mania both in Europe and the United States. "We are delighted to be submitting our application to the European health authorities so soon after our submission to the FDA" commented Geoff Birkett, global vice president, CNS, pain and infection. "Seroquel is a truly unique compound and its profile is ideal for the treatment of manic episodes associated with bipolar disorder. Use of Seroquel has been growing at a tremendous rate in Europe and feedback from patients and clinicians continues to be very positive. With its expanded indication range we are sure of further strong growth in 2003 and beyond." The application to the European health authorities follows the completion of a comprehensive bipolar disorder clinical trial program undertaken by AstraZeneca to examine the efficacy and tolerability of Seroquel in this important disease area. The program has delivered strong and positive results in both monotherapy and adjunctive therapy studies, which confirm Seroquel to be an ideal first-line agent in the treatment of manic episodes associated with bipolar disorder. The trial program consisted of four double-blind, randomized trials, involving almost 1000 patients in 28 countries. The trials assessed the effectiveness and safety of Seroquel as both monotherapy and adjunctive therapy with mood stabilizer in the treatment of manic episodes associated with bipolar disorder. "Seroquel as a treatment for bipolar disorder will offer significant benefits to European clinicians and patients," said Dr. Eduard Vieta, director of research, department of psychiatry, University of Barcelona. "Throughout the duration of the studies, Seroquel was shown to provide a substantial resolution of the various symptoms associated with manic episodes, while keeping side effects to a minimum. This is particularly critical in bipolar disorder since patients may lead full and productive lives when stable while a relapse in symptoms can cause real difficulties." Seroquel has been simultaneously submitted to the 14 European Member States participating in the Mutual Recognition Procedure. Further submissions in other markets worldwide are progressing. Seroquel is manufactured by AstraZeneca and is currently approved in more than 75 markets. Seroquel combines broad-based efficacy in the treatment of positive, negative, cognitive and affective symptoms of schizophrenia, while offering excellent tolerability. Seroquel is associated with an incidence of EPS and prolactin elevation no different to placebo across the full dosage range, a favorable weight profile, and no clinically important effects on QT interval in most patients. This article was prepared by Medical Letter on the CDC & FDA editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>
05 Март, 2003
New safety information associated with the use of ZOLOFT(tm) in patients taking pimozide
KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Canada Newswire English via NewsEdge Corporation : KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT (sertraline hydrochloride) capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Based on the result of a recent clinical study, the concomitant use of ZOLOFT and pimozide (an anti-psychotic medication) is now contraindicated. Patients are advised not to take ZOLOFT with pimozide as their interaction may result in arrhythmias (irregular heartbeats), which may be serious and life- threatening. Patients should be aware that the symptoms of possible arrhythmia include dizziness, palpitations and fainting, and that they should seek immediate medical attention if these symptoms occur. If you are presently being treated with this drug combination, please consult your physician before changing your current therapy. This advisory is in addition to a letter issued to health care professionals reminding them of the above-mentioned safety information. As well, the product monograph for ZOLOFT is being revised to inform physicians regarding potential adverse effects this drug combination may cause. If patients have questions regarding their current prescription, they are asked to contact their physician or pharmacist. VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=56403 -0- 03/05/2003 /For further information: please contact: Rhonda O'Gallagher, Senior Manager, Corporate Affairs, Pfizer Canada Inc., (514) 693-4090/ CO: ST: IN: SU: CNW 17:39e 05-MAR-03 <> << Copyright ©2003 Canada NewsWire >>
04 Март, 2003
Пополнение в разделе Пособия
04 Март, 2003
Современное учение о неврозах - Пауль Шильдер, Освальд Бумке

Современное учение о неврозах - Пауль Шильдер, Освальд Бумке

27 Февраль, 2003
Hersh & Hersh Targets Eli Lilly's Most Profitable Anti-Psychotic Drug
27/02/2003 - Hersh & Hersh Targets Eli Lilly's Most Profitable Anti-Psychotic Drug SAN FRANCISCO--(BUSINESS Representing Numerous Plaintiffs, Attorneys Aim to Enforce Prominent Labeling of Zyprexa's Acute Side Effects Business Wire via NewsEdge Corporation : SAN FRANCISCO--(BUSINESS WIRE)--Feb. 27, 2003-- Representing Numerous Plaintiffs, Attorneys Aim to Enforce Prominent Labeling of Zyprexa's Acute Side Effects Hersh & Hersh of San Francisco (www.hershlaw.com) today announced that it has already filed several complaints on behalf of plaintiffs across the U.S. against Indianapolis-based Eli Lilly & Co. Attorneys are in the process of filing numerous other complaints and plan to prove that as a result of taking Zyprexa, a drug prescribed for the treatment of schizophrenia and bipolar mania, their clients have sustained life-threatening or fatal injuries, including diabetes mellitus, hyperglycemia and pancreatitis. In some cases patients have died after long-term use of Zyprexa, even though it has been FDA-approved only as a short-term treatment, and their families have hired Hersh & Hersh to represent them in wrongful death suits against the giant drug manufacturer. Cases are being filed individually, in both Federal and State courts. According to Hersh & Hersh partner Nancy Hersh, "Eli Lilly's profits are skyrocketing from these 'atypical' anti-psychotic drugs, while patients are being kept in the dark about their damaging side effects. We believe Eli Lilly is culpable in heavily promoting Zyprexa as a safe and effective drug for psychotic disorders, yet virtually concealing the risks to doctors and their patients." Evidence of Fatal Side Effects Exposed Since 1996 Eli Lilly has widely promoted Zyprexa as the most effective medication on the market for bipolar disorder, with fewer adverse side effects than any other methods of treatment. It is also the company's top-selling drug, with reported sales of $3 billion in 2001. However in 2002, author of Mad In America and medical journalist Robert Whitaker exposed clinical trial data about Zyprexa that was not made available to most doctors prescribing the drug. According to Whitaker, "Of the 2,500 patients in the trials who received Zyprexa, 20 died; 20 committed suicide; and 22% suffered a 'serious' adverse event. Two-thirds of the Zyprexa patients did not successfully complete the trials..." In July 2002, a team of medical researchers at Duke University discovered the link between the new generation of anti-psychotic drugs like Zyprexa and early onset diabetes. They identified 289 cases of diabetes in patients who had been prescribed Zyprexa, stating, "Of the 289 cases of diabetes linked to the use of Zyprexa, 225 were newly diagnosed cases; 100 patients developed ketosis (a serious complication of diabetes); 22 people developed inflammation of the pancreas, a life-threatening condition; and 23 people died. Over 70% of these cases occurred within six months of starting the drug treatment." Numerous other medical studies have reported that Zyprexa can result in serious -- and oft-fatal -- diabetic diseases, caused by severe insulin deficiency. In one Hersh & Hersh case, the North Carolina plaintiff suffered a diabetic coma after taking Zyprexa for eight months, and had to have his left leg and right foot amputated. In spite of these dangerous side effects there is no warning in Zyprexa's product information to monitor blood glucose levels, or discontinue use if high blood sugar is noted or if the patient develops diabetes. Currently, the literature accompanying Zyprexa only alludes to diabetes and acidosis as part of a list of side effects that are purported to be very rare. In the early 1980s Hersh & Hersh began working on DES cases and was the first law firm in the Bay Area to successfully beat Eli Lilly on behalf of DES children. Today Hersh & Hersh is suing Eli Lilly for failing to adequately disclose the serious side effects of Zyprexa, and for not ameliorating the cause of these injuries even though they were "scientifically knowable" at the time of distribution. Off-Label Drug Use is Growing Problem Among the numerous cases to be filed by Hersh & Hersh attorneys, several individuals were prescribed Zyprexa for the treatment for "off label" symptoms, including anxiety and depression, even though it is FDA-approved exclusively for schizophrenia and bipolar disorder. At least one client so far has developed an irreversible neurological disorder known as Tardive Dyskinesia and is subjected to a life of repetitive, rhythmic involuntary movements such as tongue thrusting, lip smacking, chewing movements, rocking of the trunk, marching in place and repetitive sounds such as humming or grunting. Zyprexa is among a host of anti-psychotic drugs that doctors are encouraged to prescribe for off-label uses by manufacturers. According to an article published last summer in The Globe & Mail (August 13, 2002), medical ethics professor Miriam Shuchman, MD, stated that the biggest difference between the approved and unapproved use of a drug is the evidence that backs it up. To get a medical condition approved or "on-label," drug companies must convince the FDA that high-quality studies show that the drug makes a real difference for people with that condition. Off-label uses of a drug typically have not been subjected to that level of scrutiny. "To boost sales and circumvent the FDA approval process drug manufacturers like Eli Lilly are actually encouraging their sales reps to push secondary uses of these anti-psychotic drugs and regularly review reports of the frequency of doctors prescribing these meds for off-label uses," added Hersh. "In many cases, off-label sales account for the bulk of revenues generated by these drugs. Our intention in the case against Eli Lilly is to also shine a light on the severe damage caused by this kind of dubious sales and marketing practice." About Hersh & Hersh Hersh & Hersh is a San Francisco-based law firm dedicated to protecting the safety and rights of consumers. The law firm represents clients both on an individual level and in class and multi-district litigation, and has pursued and won a wide range of civil suits, from product liability, medical malpractice and insurance bad faith to sexual harassment and employee discrimination. For the past 32 years, Hersh & Hersh has been committed to using the law to protect individuals by making sure companies exercise due diligence in manufacturing their products and operate in good faith in delivering their services. CONTACT: Hersh & Hersh Shelly Gordon, 650/856-1607 (Press) sgordon g2comm.com or Lisa Byrne, 415/221-5018 (Press) lisa lisabyrne.com KEYWORD: NORTH CAROLINA INDIANA CALIFORNIA INDUSTRY KEYWORD: E-COMMERCE INTERNET LEGAL/LAW PHARMACEUTICAL GOVERNMENT CLASS ACTION LAWSUITS PRODUCT SOURCE: Hersh & Hersh Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com <> << Copyright ©2003 Business Wire >>
26 Февраль, 2003
Общая психопатология - Карл Ясперс
26 Февраль, 2003
7-я Междисциплинарная Региональная конференция по биологической психиатрии

Стресс и поведение

При поддержке International Brain Research Organisation (IBRO)

26-28 февраля 2003 г. в Москве состоится 7-я Междисциплинарная конференция по проблемам стрессорного поведения.

Цель ежегодной международной конференции, проводимой ЦФБП начиная с 1997 г собрать биологов, медиков и психологов из России и других стран СНГ для междисциплинарного обсуждения механизмов стрессорного поведения человека и животных в норме и патологии.

Темы конференции: нейрохимия и нейрофизиология поведения человека и животных, нейропсихофармакология, моделирование поведения, страх, тревога, депрессия, агрессия нейробиология и клинические аспекты, сон и его нарушения, механизмы памяти, психофизиология, нейропсихология, психиатрия, нейроэтология, этология человека

Подробная информация на веб-сайте конференции

E-mail: nem-physiol@mail.ru

Председатель конференции А.В.Калуев (Москва)
Председатель Программного комитета проф. О.Г.Сыропятов (Киев)

22 Февраль, 2003
FDA approves Prozac for use in children
LAHORE, Feb 20-PPI: Doctors can now prescribe the popular antidepressant Prozac to children suffering from depression and obsessive compulsive disorder, the US Food and Drug Administration has ruled, reports The HealthScout News Service. Pakistan Press International via NewsEdge Corporation : LAHORE, Feb 20-PPI: Doctors can now prescribe the popular antidepressant Prozac to children suffering from depression and obsessive compulsive disorder, the US Food and Drug Administration has ruled, reports The HealthScout News Service. The decision which covers children and teens seven to 17 years of age, marks the first approval of one of the newer types of antidepressants -called selective serotonin reuptake inhibitors, or SSRIs- or treating depression in children. Depression affects upto 25 per cent of children and about eight percent of teens in the United States. Obsessive Compulsive Disorder, or OCD, affects about tow percent o the population, and typically begins during adolescence or childhood. At least one-third of the cases of adult OCD begin in childhood, the National Institute of Mental Health says. Clinical trials revealed that the side effects of Prozac use in children and teens were similar to those typically experienced by adults, including nausea, tiredness, nervousness, dizziness, and difficulty concentrating, the FDA says. However, one trial in children and adolescents eight to 17 years old found that after 19 weeks of treatment with Prozac, the study participants gained, on average, about a half an inch less I height and about two pounds less in weight compared to children taking a placebo. The drug's maker, Eli Lilly, has agreed to conduct a follow up study to further evaluate any potential impact of Prozac's use on long-term growth in children, the FDA says. (THROUGH ASIA PULSE) 20-02 2003 <> << Copyright ©2003 Asia Pulse Pte Ltd. >>
20 Февраль, 2003
Cовременные аспекты клинической, экспертной и социальной проблем подростково-юношеской психиатрии

Программа постоянно действующего семинара по теме: "Современные аспекты клинической, экспертной и социальной проблем подростково-юношеской психиатрии" для психиатров, участвующих в военно-врачебной экспертизе, подростковых психиатров и психологов на 2003 год (восьмой год обучения)

 

 

ОРГАНИЗАТОРЫ:

  • ПРОБЛЕМНАЯ КОМИССИЯ «ПСИХИЧЕСКОЕ ЗДОРОВЬЕ ДЕТЕЙ, ПОДРОСТКОВ И ЮНОШЕЙ» МЕЖВЕДОМСТВЕННОГО НАУЧНОГО СОВЕТА ПО ПРОБЛЕМАМ ПСИХИЧЕСКОГО ЗДОРОВЬЯ РАМН

     

  • КОМИТЕТ ЗДРАВООХРАНЕНИЯ Г.МОСКВЫ

     

  • ФЕДЕРАЛЬНЫЙ НАУЧНО-МЕТОДИЧЕСКИЙ ЦЕНТР ОХРАНЫ ПСИХИЧЕСКОГО ЗДОРОВЬЯ ДЕТЕЙ И ПОДРОСТКОВ МЗ РФ

     

  • МЕДИКО-ПЕДАГОГИЧЕСКИЙ ЛЕЧЕБНО-РЕАБИЛИТАЦИОННЫЙ ПОДРОСТКОВЫЙ ЦЕНТР ПРИ ПСИХИАТРИЧЕСКОЙ КЛИНИЧЕСКОЙ БОЛЬНИЦЕ № 15 Г.МОСКВЫ

     

  • ЦЕНТРАЛЬНАЯ ВОЕННО-ВРАЧЕБНАЯ КОМИССИЯ МО РФ

     

    №№ пп

    Дата проведения

    Программа семинара

    Время проведения

    Руководитель семинара

    1.

    20.02.03 г.

    Психосоматические расстройства у детей и подростков

    10.00-13.00

    Северный Анатолий Алексеевич к.м.н., ст.н.с. НЦПЗ РАМН

    2.

    20.03.03 г.

    Психология агрессивного поведения у подростков и юношей

    10.00-13.00

    Ениколопов Сергей Николаевич Зав.отделом, к.п.н. НЦПЗ РАМН

    3.

    17.04.03 г.

    Объем понятия и критерии диагностики психопатии по данным катамнеза

    10.00-13.00

    Ракитин Михаил Михайлович к.м.н., доцент кафедры психиатрии и наркологии фак-та постдипломного обучения Моск.Гос. медико-стоматологического университета

    4.

    15.05.03 г.

    Клиника и терапия агрессивного поведения у подростков

    10.00-13.00

    Можгинский Юрий Борисович к.м.н., ассистент кафедры психиатрии и наркологии Моск. Гос. медико- стоматологического университета

    5.

    19.06.03 г.

    Наркомания в подростково- юношеском возрасте (особенности клиники, течения и лечения)

    10.00-13.00

    Надеждин Алексей Валентинович к.м.н., главный детский нарколог МЗ РФ

    6.

    18.09.03 г.

    Роль родительско- семейных отношений в адаптации подростков и юношей с психическими расстройствами и задачи психолога и психиатра

    10.00-13.00

    Чемекова Елена Борисовна научный сотрудник отдела клинической психологии НЦПЗ РАМН

    7.

    16.10.03 г.

    Умственная отсталость в подростково-юношеском возрасте (клинико-дифференциальная диагностика)

    10.00-13.00

    Сухотина Нина Константиновна д.м.н., руководитель отделения клинико-психологических проблем нарушения психического развития НИИ психиатрии МЗ РФ

    8.

    19.11.03 г.

    Клиника и диагностика системных невротических и неврозоподобных расстройств у подростков

    10.00-13.00

    Шевченко Юрий Степанович д.м.н., профессор, руководитель кафедры детской и подростковой психиатрии и психотерапии РМАПО

    9.

    11.12.03 г.

    Современные аспекты психофармакотерапии больных подростково-юношеского возраста

    10.00-12.00

    Олейчик Игорь Валентинович к.м.н., ст.н.с. НЦПЗ РАМН Каледа Василий Глебович, к.м.н., ст.н.с. НЦПЗ РАМН

     

     

    Медицинское освидетельствование призывников в свете нового Положения о военно-врачебной экспертизе

    12.00-13.00

    Фадеев Александр Сергеевич к.м.н., начальник отдела экспертизы военнослужащих ЦВВК МО


    Место проведения: Научный Центр психического здоровья РАМН (НЦПЗ РАМН), метро «Каширская», Каширское шоссе, 34 (авт.164, 220, 1 остановка) - конференцзал. Схема проезда.

    Ответственные:

    Главный научный сотрудник НЦПЗ РАМН
    Цуцульковская Мэлла Яковлевна
    Телефон 117-71-47

    Зав.Подростковым Центром
    Пыхтарев Валерий Николаевич
    Телефон 323-99-29, 324-41-05

    Вед.научный сотрудник НЦПЗ РАМН
    Симашкова Наталья Валентиновна
    Телефон 116-51-92